News and Comments

BIOTECHNOLOGY PROMISES A HUGE GROWTH

  Wednesday, December 21, 2011

EXELIXIS’ (EXEL) advanced PI3K-delta research and development preclinical program attracted Merck, known as MSD outside of the United States and Canada. “PI3K-delta is therapeutic target that academic researchers and the drug industry are racing to develop therapeutic antagonists for both inflammatory diseases and cancer. To get to Exelixis program, Merck agreed to pay $12 million in upfront payment in addition to potential milestone payments for multiple indications of up to $239 million and royalties on net-sales of products that would emerge from the agreement. Merck will also pay Exelixis royalties on any compounds that would emerge from Exelixis’ PI3K-delta program or from certain compounds that arise from Merck’s internal discovery efforts targeting PI3K-delta during a certain period. More...


Recent Postings


Archive


Tags

Galena (GALE) Auspex (ASPX) Anacor (ANAC) Roche (RHHBY) Global Cell Therapeutics (GBT) Dendreon (DNDN) Sangamo (SGMO) Elan (ELN) galapagos (GLPG) MODERNA Ariad (ARIA) Sarepta (SRPT) Ocular Therapeutix (OCUL) CompuGen (CGEN) Theravance Bio Pharma (TBPH) Roche (ROCHE) BIOMARIN (BMRN) KITE (KITE) GUARDIAN HEALTH Exelixis (EXEL) Telaprevir Amgen (AMGN) SERES THERAPEUTICS (MCRB) Anadys (ANDS) Agenus (AGEN) SUNESIS PHARMACEUTICALS (SNSS) GlaxoSmithKline (GSK) Array Pharmaceuticals (ARRY) NEUROCRINE (NBIX) AstraZeneca (AZN) C4 Therapeutics Human Longevity (HLI) Merck (MRK) Jazz Pharmaceuticals (JAZZ) ADVENTRIX (ANX) Dynavax (DVAX) OSI (OSIP) Incyte (INCY) ABBVIE (ABBV) Intrexon (XON) Alder Biopharmaceuticals (ALDR) JUNO (JUNO) ARGOS (ARGS) Multiple Myeloma Idenix (IDIX) Alnylam (ALNY) ImmunoGen (IMGN) Intercept (ICPT) Trastuzumab-DM1 Mirati Therapeutics (MRTX) Prosensa (RNA) Ziofpharm (ZIOP) KERYX (KERX) Sanofi (SNA) OncoCyte (OCX) Sequenom (SQNM) Sanofi-Aventis (SAN) NANTKWEST (NK) Cytokinetics (CYTK) Zerenex Rapamune Editas (EDIT) Biocryst (BCRX) PTC Therapeutics (PTCT) Prolor Biotech (PBTH) LEXICON (LXRX) Theravance (THRX) Aimmune Therapeutics (AIMT) CEMPRA (CEMP) Tysabri ZALTRAP™ JOUNCE THERAPEUTICS (JNCE) NOVOCURE (NVCR) IDERA (IDRA) AGOS (ARGS) SYNTA (SNTA) Sanofi (SNY) Advaxis (ADXS) Spike Therapeutics (ONCE) Biogen Idec (BIIB) VANDA (VNDA) ARCA (ABIO) Ridaforolimus Endometrial Cancer CRISPR Therapeutics (CRSP) Inovio (INO) REGULUS (RGLS) NEKTAR (NKTR)) Intermune (ITMN) HALOZYME (HALO) Regeneron (REGN) Herceptin Benlysta (belimumab) Adaptimmune (ADAP) Bristol-Myers Squibb (BMY) Vitae Pharmaceuticals (VTAE) ACADIA (ACAD) Valeant Pharmaceuticals International (VRX) Micromet (MITI) Velcade (bortezomib) Ionis (IONS) Agenus (AGEN INNOVIVA (INVA) PORTOLA (PTLA) AERIE PHARMACEUTICALS Gilead (GILD) Seattle Genetics (SGEN) Pluristem (PSTI) Revlimid (lenolidamide) RenenxBio (RGNX) ISIS (ISIS) Genentech Bellicum (BLCM) Abbott Laboratories (ABT) Vertex (VRTX) Human Genome Sciences (HGSI) Onyx (ONXX) TOKAI (TKAOI) Xoma (XOMA) Illumina (ILMN)